Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Friday 13 May, 2022

Omega Diagnostics Gp

Posting of Circular and Notice of General Meeting

RNS Number : 4443L
Omega Diagnostics Group PLC
13 May 2022
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Posting of Circular and Notice of General Meeting

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces, further to the announcement of 6 May 2022, a Circular containing details of the Open Offer and convening the General Meeting, together with a Form of Proxy will be posted to Shareholders today.

The General Meeting will be held at the offices of Shepherd & Wedderburn, 1 Exchange Crescent, Conference Square, Edinburgh, EH3 8UL at 11.00 a.m. on 6 June 2022. A copy of the Circular will today be made available on the Company's website: http://www.omegadiagnostics.com/Investor-Relations/Corporate-Information

 

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's announcement dated 6 May 2022.

 

 

Contacts: 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)


Alice Lane/ Harriet Ward (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGEANSDFEEAEEA

a d v e r t i s e m e n t